We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.

Novo Nordisk Announces BLA Submission for Extended Half-Life FVIII Therapy

Genentech  informed NHF of a postmarketing fatality that has occurred in an elderly patient who received treatment with emicizumab- kxwh (Hemlibra) for acquired hemophilia A.

According to a recent study, most post pubertal girls and adolescents who experience heavy menstrual bleeding are not screened for von Willebrand disease (VWD), despite years of recommendations from the American College of Obstetricians and Gynecologists. Investigators came to this conclusion after conducting a retrospective analysis of a national claims database of public and privately insured individuals from 2011-2013.  

Study Shows VWD Testing Remains Low

Most postpubertal girls and adolescents who experience heavy menstrual bleeding are not screened for von Willebrand disease (VWD), despite years of recommendations from the American College of Obstetricians and Gynecologists.

Prophylaxis study results for boys with severe hemophilia A

Researchers investigated an approach to prophylactic therapy in which patients began by receiving weekly infusions of standard half-life recombinant factor VIII and ultimately transition to “tailored frequency-escalated prophylaxis."

Honoring the Past, Embracing the Future

NHF's Red Tie Soiree paid tribute to longtime advocates for the bleeding disorders community while looking forward to the future of research and treatment.

Subscribe to Our Newsletter

Fill in the fields below to receive our email newsletter.